Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas O Escrivani

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Plos Pathogens|July 17, 2023
Competition among variants is predictable and contributes to the antigenic variation dynamics of African trypanosomesDouglas O Escrivani, Viktor Scheidt, Michele Tinti, et al.
Plos Pathogens|March 25, 2026
Genetic origins and proteomic consequences of kinetoplast loss in trypanosomesMelanie Ridgway, Douglas O Escrivani, Markéta Novotná, et al.
Parasitology|May 5, 2020
Single-dose treatment for cutaneous leishmaniasis with an easily synthesized chalcone entrapped in polymeric microparticlesAriane J Sousa-Batista, Natalia Arruda-Costa, Douglas O Escrivani, et al.
Nucleic Acids Research|October 21, 2025
A non-coding role for trypanosome VSG transcripts in allelic exclusionDouglas O Escrivani, Sebastian Hutchinson, Michele Tinti, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|November 2, 2019
Encapsulation in lipid-core nanocapsules improves topical treatment with the potent antileishmanial compound CH8Douglas O Escrivani, Milene Valéria Lopes, Fernanda Poletto, et al.
RSC Medicinal Chemistry|February 28, 2025
Simple accessible clemastine fumarate analogues as effective antileishmanialsRebecca L Charlton, Douglas O Escrivani, Christopher Brown, et al.
ACS Infectious Diseases|December 9, 2020
Antileishmanial Chemotherapy through Clemastine Fumarate Mediated Inhibition of the <i>Leishmania</i> Inositol Phosphorylceramide SynthaseJohn G M Mina, Rebecca L Charlton, Edubiel Alpizar-Sosa, et al.
Plos Neglected Tropical Diseases|November 15, 2021
Chalcones identify cTXNPx as a potential antileishmanial drug targetDouglas O Escrivani, Rebecca L Charlton, Marjolly B Caruso, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Plos Pathogens|July 17, 2023
Competition among variants is predictable and contributes to the antigenic variation dynamics of African trypanosomesDouglas O Escrivani, Viktor Scheidt, Michele Tinti, et al.
Plos Pathogens|March 25, 2026
Genetic origins and proteomic consequences of kinetoplast loss in trypanosomesMelanie Ridgway, Douglas O Escrivani, Markéta Novotná, et al.
Parasitology|May 5, 2020
Single-dose treatment for cutaneous leishmaniasis with an easily synthesized chalcone entrapped in polymeric microparticlesAriane J Sousa-Batista, Natalia Arruda-Costa, Douglas O Escrivani, et al.
Nucleic Acids Research|October 21, 2025
A non-coding role for trypanosome VSG transcripts in allelic exclusionDouglas O Escrivani, Sebastian Hutchinson, Michele Tinti, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|November 2, 2019
Encapsulation in lipid-core nanocapsules improves topical treatment with the potent antileishmanial compound CH8Douglas O Escrivani, Milene Valéria Lopes, Fernanda Poletto, et al.
RSC Medicinal Chemistry|February 28, 2025
Simple accessible clemastine fumarate analogues as effective antileishmanialsRebecca L Charlton, Douglas O Escrivani, Christopher Brown, et al.
ACS Infectious Diseases|December 9, 2020
Antileishmanial Chemotherapy through Clemastine Fumarate Mediated Inhibition of the <i>Leishmania</i> Inositol Phosphorylceramide SynthaseJohn G M Mina, Rebecca L Charlton, Edubiel Alpizar-Sosa, et al.
Plos Neglected Tropical Diseases|November 15, 2021
Chalcones identify cTXNPx as a potential antileishmanial drug targetDouglas O Escrivani, Rebecca L Charlton, Marjolly B Caruso, et al.
Pageof 1